Transfusion in Critical Care — Part 2: Platelet, Plasma & Cryoprecipitate Transfusion
Evidence-based indications, thresholds, and dosing for platelet, plasma (FFP/FP24), and cryoprecipitate/fibrinogen concentrate transfusion, including platelet refractoriness, warfarin reversal, and special considerations for HIT, TTP, ITP, and DIC.
1. Platelet Transfusion
1.1 Platelet Products — Overview
| Product | Description | Platelet Content | Volume | Shelf Life | Storage |
|---|---|---|---|---|---|
| Apheresis platelets (single-donor) | Collected from a single donor via apheresis; equivalent to 4–6 pooled random donor units | ≥ 3.0 × 10¹¹ per unit | 200–300 mL | 5 days (with agitation) | 20–24°C with continuous gentle agitation |
| Pooled random donor platelets | Whole-blood-derived platelets from 4–6 donors, pooled into a single bag | ≥ 3.0 × 10¹¹ per pool | 250–350 mL | 5 days from collection (4 hours after pooling) | 20–24°C with continuous gentle agitation |
| Pathogen-reduced platelets | Treated with pathogen inactivation technology (e.g., amotosalen/UVA, riboflavin/UV) | Slightly reduced count post-treatment | Similar | 5–7 days (depending on system) | 20–24°C with continuous gentle agitation |
Key distinctions:
- Apheresis platelets are preferred when minimizing donor exposure is important (e.g., to reduce HLA alloimmunization risk, for CMV risk reduction, or in patients who may need long-term platelet support)
- One apheresis platelet unit is therapeutically equivalent to one pooled random-donor platelet dose
- Standard adult dose: one apheresis unit or one pooled random-donor unit (both provide ≥ 3.0 × 10¹¹ platelets)
1.2 Expected Platelet Count Increment
| Parameter | Value |
|---|---|
| Expected increment per dose (in a 70 kg adult without consumptive process) | 30,000–50,000/μL |
| Corrected count increment (CCI) | (Post-transfusion count − Pre-transfusion count) × BSA (m²) ÷ Number of platelets transfused (× 10¹¹) |
| Adequate CCI at 1 hour | ≥ 7,500 |
| Adequate CCI at 24 hours | ≥ 4,500 |
| Timing of post-transfusion count | 10–60 minutes after completion (for refractoriness evaluation); 18–24 hours (for survival assessment) |
1.3 Platelet Transfusion Thresholds
The following thresholds are recommended by the major transfusion medicine and hematology professional societies.1 2
| Clinical Scenario | Platelet Transfusion Trigger | Strength | Notes |
|---|---|---|---|
| Prophylactic — stable, non-bleeding | < 10,000/μL | Strong recommendation, moderate-quality evidence | Applies to chemotherapy-induced thrombocytopenia, bone marrow failure; reduces spontaneous mucosal and intracranial bleeding risk |
| Fever, sepsis, or DIC (non-bleeding) | < 10,000–20,000/μL | Conditional recommendation | Higher threshold due to increased platelet consumption and bleeding risk |
| Minor procedures (central line insertion, paracentesis, thoracentesis) | < 20,000/μL | Conditional recommendation | Some evidence supports safety of procedures at lower thresholds with ultrasound guidance |
| Lumbar puncture | < 40,000–50,000/μL | Conditional recommendation | Risk of spinal hematoma; threshold varies by institutional protocol |
| Major surgery / invasive procedures | < 50,000/μL | Strong recommendation | Standard surgical hemostasis threshold |
| Neuraxial anesthesia (epidural, spinal) | < 80,000/μL | Conditional recommendation | Based on anesthesiology society guidelines; risk of epidural hematoma |
| Neurosurgery / intracranial procedures | < 100,000/μL | Strong recommendation | High risk of intracranial hemorrhage; some centers require > 100,000/μL |
| Ocular surgery (posterior chamber) | < 50,000–100,000/μL | Conditional recommendation | Varies by procedure |
| Active bleeding | < 50,000/μL (< 100,000/μL for CNS or severe hemorrhage) | Strong recommendation | Transfuse to maintain > 50,000/μL during active bleeding; > 100,000/μL for intracranial or life-threatening hemorrhage |
| Massive transfusion | < 50,000/μL (or per MTP protocol — typically included after every 6–10 units RBC) | Strong recommendation | See Part 3 for MTP details |
| Cardiac surgery (CPB) | Clinical bleeding + < 50,000–100,000/μL | Conditional recommendation | CPB causes platelet dysfunction; functional platelet assessment may be more valuable than count alone |
1.4 Situations Where Platelet Transfusion Is NOT Indicated or Is Contraindicated
| Condition | Recommendation | Rationale |
|---|---|---|
| Heparin-induced thrombocytopenia (HIT) | Avoid platelet transfusion unless life-threatening hemorrhage | Platelet transfusion may fuel thrombotic process; can worsen thrombosis; discontinue heparin and start alternative anticoagulant (argatroban, bivalirudin) |
| Thrombotic thrombocytopenic purpura (TTP) | Avoid platelet transfusion unless life-threatening hemorrhage | Platelet transfusion may worsen microvascular thrombosis; initiate therapeutic plasma exchange (TPE) urgently |
| Immune thrombocytopenic purpura (ITP) | Not routinely indicated — platelets have very short survival | Treat underlying autoimmune process (corticosteroids, IVIG, anti-D, TPO-receptor agonists); platelet transfusion only for life-threatening hemorrhage (give in conjunction with IVIG for transient benefit) |
| Drug-induced thrombocytopenia | Discontinue offending drug; transfuse only if bleeding or profound thrombocytopenia (< 10,000/μL) | Recovery expected once drug is cleared |
| Thrombocytopenia due to splenic sequestration | Platelet transfusion provides minimal increment | Spleen sequesters transfused platelets; treat underlying cause |
1.5 Platelet Refractoriness
Platelet refractoriness is defined as a repeatedly inadequate post-transfusion platelet increment (CCI < 7,500 at 1 hour on two consecutive occasions with ABO-compatible, fresh platelets).2
Causes of Platelet Refractoriness
| Category | Cause | Frequency | Mechanism |
|---|---|---|---|
| Non-immune (80% of cases) | Fever | Very common | Increased platelet consumption |
| Sepsis / infection | Very common | Increased consumption, DIC | |
| DIC | Common | Consumptive coagulopathy | |
| Splenomegaly | Common | Splenic sequestration (up to 90% of platelets) | |
| Medications (amphotericin B, vancomycin, heparin, antibiotics) | Common | Drug-dependent platelet destruction | |
| Bleeding | Common | Ongoing consumption | |
| Immune (20% of cases) | HLA alloimmunization (Class I HLA antibodies) | Most common immune cause | Anti-HLA antibodies destroy transfused platelets |
| Platelet-specific antibodies (anti-HPA) | Rare | Antibodies to human platelet antigens | |
| ABO incompatibility | Common but often overlooked | ABO antigens on platelet surface; ABO-incompatible platelets have ~20% lower increment | |
| Drug-dependent antibodies | Rare | Drug-antibody-platelet complexes |
Evaluation of Platelet Refractoriness — Stepwise Approach
- Confirm refractoriness: Obtain 10-minute and 1-hour post-transfusion platelet counts on two consecutive transfusion occasions using ABO-compatible, fresh (< 3 days old) platelets
- Calculate CCI: CCI < 7,500 at 1 hour confirms refractoriness
- Evaluate for non-immune causes (present in 80% of refractory patients):
- Active infection, fever, DIC, splenomegaly, medications, active bleeding
- If non-immune cause identified: address underlying cause; platelet transfusion may still be given if indicated despite expected poor increment
- If non-immune causes excluded — evaluate for immune cause:
- Send HLA antibody screen (panel-reactive antibody testing for Class I HLA antibodies)
- Send platelet crossmatch if available
- Management of HLA-mediated refractoriness:
- HLA-matched platelets (best match: A-grade, 4-antigen match at HLA-A and HLA-B)
- HLA-selected platelets (B-grade: partial match or antigen-negative based on antibody specificity)
- Crossmatch-compatible platelets (selected by platelet crossmatch testing)
- HLA-matched platelets require a large donor registry; availability may be limited
- If anti-HPA antibodies suspected: HPA genotyping and HPA-matched platelets (very rare; consult transfusion medicine)
1.6 ABO Compatibility for Platelet Transfusion
While ABO-identical platelets are preferred, ABO-incompatible platelet transfusions are commonly given when ABO-identical products are unavailable.
| Compatibility Type | Description | Clinical Impact |
|---|---|---|
| ABO-identical | Donor and recipient same ABO type | Optimal increment; preferred |
| ABO-compatible (minor incompatibility) | Donor plasma compatible with recipient RBCs (e.g., A platelets to AB recipient) | Acceptable; minimal risk |
| ABO-incompatible (major) | Donor platelet A/B antigens incompatible with recipient plasma antibodies (e.g., A platelets to O recipient) | ~20% lower platelet increment; generally acceptable for most clinical situations |
| ABO-incompatible (minor — high-titer) | Donor plasma contains high-titer anti-A or anti-B (typically group O donors) | Risk of hemolysis of recipient RBCs; some blood banks test for high-titer antibodies and preferentially avoid these units |
2. Plasma Transfusion
2.1 Plasma Products — Overview
| Product | Description | Factor Content | Storage | Thaw Time | Post-Thaw Shelf Life |
|---|---|---|---|---|---|
| Fresh frozen plasma (FFP) | Frozen within 8 hours of collection | All coagulation factors at normal levels; fibrinogen ≥ 200 mg/dL per unit | ≤ −18°C (up to 1 year) | 20–30 minutes (37°C water bath) | 24 hours at 1–6°C (relabeled as “thawed plasma”) |
| FP24 (Frozen plasma within 24 hours) | Frozen within 24 hours of collection | Slightly lower Factor V and Factor VIII (~80–85% of FFP levels); all other factors normal | ≤ −18°C (up to 1 year) | 20–30 minutes | 24 hours at 1–6°C |
| Thawed plasma | FFP or FP24 that has been thawed and stored at 1–6°C | Factor VIII and Factor V decline progressively (50–60% of initial levels by day 5); fibrinogen, Factor VII, Factor II, Factor IX, Factor X remain adequate | 1–6°C | Already thawed | 5 days at 1–6°C |
| Liquid plasma (never frozen) | Separated from whole blood; never frozen | Factor VIII levels reduced; stable factors preserved | 1–6°C | N/A (already liquid) | 26 days (CPDA-1) or 40 days (additive solutions) |
| Solvent/detergent-treated plasma | Pooled, pathogen-inactivated plasma | Standardized factor levels across pool; reduced TRALI risk (pooling dilutes HLA antibodies) | ≤ −18°C | Per product specifications | Per product specifications |
Key clinical notes:
- For most ICU indications (active bleeding with coagulopathy, DIC), FFP and thawed plasma are interchangeable — minor reductions in labile factors are not clinically significant
- Thawed plasma (5-day shelf life) is increasingly used by trauma centers and blood banks to reduce waste and ensure immediate availability
- Liquid plasma is used in some trauma centers for massive transfusion — it does not require thawing, allowing immediate availability
2.2 Plasma Transfusion Indications
| Indication | Recommended | Notes |
|---|---|---|
| Active bleeding with coagulopathy (INR > 1.5 or aPTT > 1.5× normal) | Yes — strong recommendation | The primary evidence-based indication; correct coagulopathy to achieve hemostasis |
| Massive transfusion | Yes — as part of MTP (see Part 3) | Typically 1:1:1 ratio with RBCs and platelets; or TEG/ROTEM-guided |
| DIC with active bleeding | Yes — conditional recommendation | Replace consumed factors; treat underlying cause simultaneously |
| Urgent warfarin reversal (life-threatening bleeding) | Yes, but 4-factor PCC preferred | FFP can be used if PCC unavailable; requires larger volume and longer infusion time; does not fully correct INR |
| TTP — therapeutic plasma exchange (TPE) | Yes — plasma is the replacement fluid for TPE | Not for transfusion per se but as replacement fluid in plasmapheresis; urgent TPE is the primary treatment for TTP |
| Coagulation factor deficiency (when specific factor concentrate unavailable) | Yes — conditional | Specific factor concentrates preferred when available (e.g., Factor VIII for hemophilia A, Factor IX for hemophilia B) |
| Liver disease with active bleeding | Yes — conditional | INR in liver disease does not reliably predict bleeding risk; balanced hemostasis (both pro- and anti-coagulant factors reduced); plasma may paradoxically worsen portal hypertension via volume expansion |
2.3 Plasma — NOT Indicated
| Clinical Scenario | Recommendation | Rationale |
|---|---|---|
| Mild INR elevation (1.5–1.8) without bleeding | Do NOT transfuse | Plasma does not reliably correct mild INR elevations; risk of volume overload outweighs theoretical benefit; an INR of 1.5–1.8 does not predict increased surgical bleeding risk |
| Volume resuscitation | Do NOT use as volume expander | Crystalloid and colloid are appropriate volume expanders; plasma carries infectious, immunologic, and volume overload risks |
| Nutritional supplementation (albumin replacement) | Do NOT use | Albumin solutions are available for this purpose if indicated |
| “Prophylactic” correction of INR before minor procedures | Generally not recommended for INR < 1.5–1.8 | Evidence suggests minor procedures (central line, paracentesis) are safe with INR up to 2.0–3.0 when performed by experienced operators |
| Reversal of direct oral anticoagulants (DOACs) | Do NOT use — specific reversal agents available | Idarucizumab for dabigatran; andexanet alfa or 4-factor PCC for factor Xa inhibitors |
2.4 Plasma Dosing
| Parameter | Recommendation |
|---|---|
| Standard dose | 10–15 mL/kg body weight |
| Typical volume per unit | 200–250 mL per unit |
| Number of units for a 70 kg adult | 4 units (≈ 800–1,000 mL) |
| Expected INR correction | Typical correction from INR 2.0 → 1.4–1.6 with standard dose; limited efficacy for INR < 1.8 → 1.5 |
| Infusion rate | 10–20 mL/min (caution in patients at risk for TACO) |
| Post-transfusion monitoring | Repeat PT/INR and aPTT 15–30 minutes after completion |
Important limitations:
- Plasma has a dose-response plateau — INR values below approximately 1.5 are very difficult to correct with additional plasma
- Large volumes may cause TACO — the most common serious adverse event associated with plasma transfusion
- Time to prepare: Thawing FFP takes 20–30 minutes; pre-thawed plasma or liquid plasma eliminates this delay
2.5 Warfarin Reversal — 4-Factor PCC vs FFP
For urgent or life-threatening bleeding in patients on warfarin, 4-factor prothrombin complex concentrate (PCC) is the preferred agent over FFP.3 4
| Parameter | 4-Factor PCC | FFP |
|---|---|---|
| Composition | Concentrated Factors II, VII, IX, X; Protein C and Protein S | All coagulation factors at physiologic concentrations |
| Volume | Small (20–40 mL per vial; total dose typically 75–150 mL) | Large (10–15 mL/kg; typically 800–1,200 mL for a 70 kg adult) |
| Dosing | INR-based: INR 2–4 → 25 units/kg; INR 4–6 → 35 units/kg; INR > 6 → 50 units/kg (max 5,000 units) | 10–15 mL/kg |
| Time to INR correction | 15–30 minutes | 4–6 hours (includes thaw time and infusion time) |
| INR correction efficacy | Superior — achieves INR ≤ 1.3 in > 60% of patients | Inferior — rarely achieves INR ≤ 1.3; typical post-transfusion INR 1.4–1.8 |
| TACO risk | Very low (small volume) | Significant (large volume, especially in elderly, heart failure) |
| Infectious risk | Very low (virally inactivated product) | Present (standard blood product) |
| TRALI risk | None (no donor plasma) | Present |
| Thrombotic risk | Rare but reported | Very low |
| Vitamin K co-administration | Required — IV vitamin K 10 mg with PCC (PCC effect is transient; vitamin K required to sustain factor production) | Required — same rationale |
| Availability | Requires pharmacy stocking; specific dosing calculation | Available from blood bank |
| Cost | Higher per-dose cost | Lower per-unit cost but higher total cost when complications considered |
Recommendation: For urgent warfarin reversal with life-threatening or intracranial hemorrhage, administer 4-factor PCC (dosed by INR) plus IV vitamin K 10 mg simultaneously. FFP remains a reasonable alternative when PCC is unavailable.3 4
3. Cryoprecipitate and Fibrinogen Concentrate
3.1 Cryoprecipitate — Product Characteristics
| Parameter | Value |
|---|---|
| Composition | Fibrinogen (≥ 150 mg per unit); Factor VIII (≥ 80 IU per unit); Factor XIII; von Willebrand Factor (vWF); Fibronectin |
| Volume | 10–15 mL per unit |
| Standard adult dose | 10 units (one “pool” of 10 individual units) |
| Expected fibrinogen rise | 50–70 mg/dL per 10-unit dose (in a 70 kg adult) |
| Storage | ≤ −18°C (frozen); 1-year shelf life |
| Thaw time | 10–15 minutes (37°C water bath) |
| Post-thaw shelf life | 6 hours at 20–24°C (individual units); 4 hours (pooled cryoprecipitate) |
| ABO compatibility | ABO-compatible preferred (small volume of plasma may contain anti-A/anti-B); not strictly required |
3.2 Fibrinogen Concentrate
| Parameter | Value |
|---|---|
| Product | Purified, lyophilized, virally inactivated fibrinogen concentrate |
| Available preparations | RiaSTAP (US); Haemocomplettan P (Europe) |
| Advantages over cryoprecipitate | Rapid reconstitution (no thaw time); standardized fibrinogen content; virally inactivated; small volume; no ABO compatibility required; room temperature storage |
| Standard adult dose | 2–4 g (typically raises fibrinogen by 60–100 mg/dL in a 70 kg adult) |
| Dose calculation | Dose (g) = [Target fibrinogen (mg/dL) − Measured fibrinogen (mg/dL)] × Plasma volume (dL) ÷ 100; Plasma volume ≈ 0.04 × Body weight (kg) × 10 |
| Reconstitution time | 5–10 minutes |
| Cost | Significantly higher than cryoprecipitate |
3.3 Indications for Fibrinogen Replacement
| Clinical Scenario | Threshold for Treatment | Product Choice | Notes |
|---|---|---|---|
| Active bleeding with hypofibrinogenemia | Fibrinogen < 150–200 mg/dL | Cryoprecipitate 10 units OR fibrinogen concentrate 2–4 g | Most common indication in the ICU |
| Massive transfusion | Fibrinogen < 150–200 mg/dL (or TEG/ROTEM showing fibrinogen deficiency) | Cryoprecipitate 10 units per MTP cycle OR fibrinogen concentrate | Fibrinogen is the first factor to reach critically low levels in massive hemorrhage |
| DIC with active bleeding | Fibrinogen < 100–150 mg/dL | Cryoprecipitate 10 units; repeat as needed | Treat underlying cause simultaneously |
| Cardiac surgery with excessive bleeding | Fibrinogen < 200 mg/dL (or ROTEM FIBTEM A5 < 8–12 mm) | Fibrinogen concentrate 2–4 g or cryoprecipitate 10 units | Evidence supports fibrinogen replacement in post-CPB bleeding5 |
| Obstetric hemorrhage | Fibrinogen < 200 mg/dL (fibrinogen < 200 mg/dL is a strong predictor of progression to severe PPH) | Cryoprecipitate or fibrinogen concentrate | Fibrinogen level is a key predictor of severity in postpartum hemorrhage |
| Congenital fibrinogen deficiency | As directed by hematology | Fibrinogen concentrate preferred | Rare; includes afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia |
| Thrombolytic-associated bleeding | Fibrinogen < 100 mg/dL with bleeding | Cryoprecipitate 10 units | Fibrinolysis from tPA, tenecteplase, etc. |
3.4 Indications Where Cryoprecipitate Is NOT Appropriate
- Factor VIII deficiency (Hemophilia A): Use recombinant Factor VIII or plasma-derived Factor VIII concentrate
- von Willebrand Disease: Use vWF/Factor VIII concentrate (Humate-P, Wilate) or desmopressin (DDAVP) for type 1 vWD; cryoprecipitate is a last resort only if specific concentrates unavailable
- Nutritional supplementation or volume expansion: Never appropriate
4. Disseminated Intravascular Coagulation (DIC) — Transfusion Management
DIC is a consumptive coagulopathy that may present with bleeding, thrombosis, or both. Transfusion support is directed at replacing consumed factors and platelets in the setting of clinically significant bleeding.6
4.1 DIC — Transfusion Support Summary
| Component | Indication | Dose | Target |
|---|---|---|---|
| Platelets | Platelet count < 10,000/μL (prophylactic) or < 50,000/μL with active bleeding | 1 apheresis unit or 1 pooled random-donor dose | > 50,000/μL if bleeding |
| FFP/Plasma | PT/INR > 1.5× normal with active bleeding | 10–15 mL/kg | Normalize PT/INR to < 1.5 |
| Cryoprecipitate | Fibrinogen < 100–150 mg/dL with active bleeding | 10 units | Fibrinogen > 150 mg/dL |
| RBC | Per standard transfusion thresholds (Hb ≤ 7 g/dL) or active hemorrhage | Per Part 1 guidelines | Hb > 7 g/dL |
4.2 Key Principles in DIC Management
- Treat the underlying cause — this is the single most important intervention (sepsis, malignancy, obstetric complication, trauma)
- Transfuse only if bleeding — prophylactic component replacement in non-bleeding DIC is generally not recommended, with the exception of platelets < 10,000/μL
- Monitor fibrinogen closely — fibrinogen is the first factor to reach critical levels in acute DIC; serial monitoring every 4–6 hours guides cryoprecipitate replacement
- Consider anticoagulation in thrombosis-predominant DIC (e.g., purpura fulminans, large-vessel thrombosis) — heparin or LMWH may be appropriate in consultation with hematology
- Do NOT give antifibrinolytics (TXA, aminocaproic acid) in DIC unless there is clear primary hyperfibrinolysis (e.g., acute promyelocytic leukemia) — antifibrinolytics may worsen microvascular thrombosis in consumptive DIC
5. Special Transfusion Considerations
5.1 Neonatal and Pediatric Transfusion
While this guideline focuses on adult critical care, key differences in pediatric transfusion include:
- RBC transfusion volumes are weight-based: 10–15 mL/kg
- Platelet transfusion volumes: 5–10 mL/kg
- CMV-seronegative or leukoreduced products should be used for neonates
- Irradiated products required for neonatal exchange transfusion, intrauterine transfusion, and immunodeficient neonates
5.2 Rh(D) Immunoglobulin (RhIG) Considerations
- Rh-negative females of childbearing potential who receive Rh-positive platelet products should receive RhIG (Rh immunoglobulin) to prevent Rh alloimmunization
- Dose: 300 μg RhIG covers up to 15 mL of D-positive RBCs (approximately 30 mL of whole blood); one dose covers approximately 5 apheresis platelet units
- RhIG is not required for plasma or cryoprecipitate transfusions (no RBC content)
References
Kaufman RM, Djulbegovic B, Gernsheimer T, et al. “Platelet Transfusion: A Clinical Practice Guideline From the AABB.” Ann Intern Med. 2015;162(3):205-213. DOI: 10.7326/M14-1589 ↩︎
Estcourt LJ, Birchall J, Allard S, et al. “Guidelines for the Use of Platelet Transfusions.” Br J Haematol. 2017;176(3):365-394. DOI: 10.1111/bjh.14423 ↩︎ ↩︎
Tomaselli GF, Mahaffey KW, Cuker A, et al. “2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants.” J Am Coll Cardiol. 2020;76(5):594-622. DOI: 10.1016/j.jacc.2020.04.053 ↩︎ ↩︎
Sarode R, Milling TJ Jr, Refaai MA, et al. “Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting with Major Bleeding: A Randomized, Plasma-Controlled, Phase IIIb Study.” Circulation. 2013;128(11):1234-1243. DOI: 10.1161/CIRCULATIONAHA.113.002283 ↩︎ ↩︎
Ranucci M, Baryshnikova E, Crapelli GB, et al. “Randomized, Double-Blinded, Placebo-Controlled Trial of Fibrinogen Concentrate Supplementation after Complex Cardiac Surgery.” J Am Heart Assoc. 2015;4(6):e002066. DOI: 10.1161/JAHA.115.002066 ↩︎
Levi M, Toh CH, Thachil J, Watson HG. “Guidelines for the Diagnosis and Management of Disseminated Intravascular Coagulation.” Br J Haematol. 2009;145(1):24-33. DOI: 10.1111/j.1365-2141.2009.07600.x ↩︎